Abstract
This paper reports the synthesis of a panel of small molecules with arylamides and arylsulfonamides groups and their biological activity in inhibiting nucleotide exchange on human Ras. The design of these molecules was guided by experimental and molecular modelling data previously collected on similar compounds. Aim of this work is the validation of the hypothesis that a phenyl hydroxylamine group linked to a second aromatic moiety generates a pharmacophore capable to interact with Ras and to inhibit its activation. In vitro experiments on purified human Ras clearly show that the presence of an aromatic hydroxylamine and a sulfonamide group in the same molecule is a necessary condition for Ras binding and nucleotide exchange inhibition. The inhibitor potency is lower in molecules in which either the hydroxylamine has been replaced by other functional groups or the sulfonamide has been replaced by an amide. In the case both these moieties, the hydroxylamine and sulfonamide are absent, inactive compounds are obtained.
Keywords: Ras, anticancer agents, computational chemistry, structure-activity relationship
Current Cancer Drug Targets
Title: Structure-Activity Studies on Arylamides and Arysulfonamides Ras Inhibitors
Volume: 10 Issue: 2
Author(s): S. Colombo, A. Palmioli, C. Airoldi, R. Tisi, S. Fantinato, S. Olivieri, L. De Gioia, E. Martegani and F. Peri
Affiliation:
Keywords: Ras, anticancer agents, computational chemistry, structure-activity relationship
Abstract: This paper reports the synthesis of a panel of small molecules with arylamides and arylsulfonamides groups and their biological activity in inhibiting nucleotide exchange on human Ras. The design of these molecules was guided by experimental and molecular modelling data previously collected on similar compounds. Aim of this work is the validation of the hypothesis that a phenyl hydroxylamine group linked to a second aromatic moiety generates a pharmacophore capable to interact with Ras and to inhibit its activation. In vitro experiments on purified human Ras clearly show that the presence of an aromatic hydroxylamine and a sulfonamide group in the same molecule is a necessary condition for Ras binding and nucleotide exchange inhibition. The inhibitor potency is lower in molecules in which either the hydroxylamine has been replaced by other functional groups or the sulfonamide has been replaced by an amide. In the case both these moieties, the hydroxylamine and sulfonamide are absent, inactive compounds are obtained.
Export Options
About this article
Cite this article as:
Colombo S., Palmioli A., Airoldi C., Tisi R., Fantinato S., Olivieri S., De Gioia L., Martegani E. and Peri F., Structure-Activity Studies on Arylamides and Arysulfonamides Ras Inhibitors, Current Cancer Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/156800910791054185
DOI https://dx.doi.org/10.2174/156800910791054185 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology Synthesis and Biological Properties of Dihydro-Oxadiazine-Based Heterocyclic Derivatives
Mini-Reviews in Medicinal Chemistry Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A
Current Medicinal Chemistry Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Pathophysiology of Thrombosis and Potential Targeted Therapies in Antiphospholipid Syndrome
Current Vascular Pharmacology Lipoprotein(a): Medical Treatment Options for an Elusive Molecule
Current Pharmaceutical Design Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Natural Products as Promising Antitumoral Agents in Breast Cancer: Mechanisms of Action and Molecular Targets.
Mini-Reviews in Medicinal Chemistry Terpyridines and their Complexes with First Row Transition Metal Ions:Cytotoxicity, Nuclease Activity and Self-Assembly of Biomacromolecules
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Humanized SCID Mice Models of SLE
Current Pharmaceutical Design Serum Vitamin E (α-Tocopherol) Estimation: A Potential Biomarker of Antioxidant Status Evaluation on Heavy Metal Toxicities
Recent Patents on Biomarkers Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design The Role of Histone Demethylase GASC1 in Cancer and its Therapeutic Potential
Current Cancer Therapy Reviews Development of Non-Coding RNAs as Biomarkers in Tumors of Digestive System
Anti-Cancer Agents in Medicinal Chemistry Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry